3B BlackBio DxBOM:532067 -2.92%68 ROA % is 10.11% as of Mar. 2026, which is 38% below its 10-year median of 16.21. GuruFocus rates BOM:532067 with a GF Score™ of 68/100 and a GF Value™ of ₹2,108.96 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, 3B BlackBio Dx ranks better than 95.12% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. 3B BlackBio Dx's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹382 Mil.
3B BlackBio Dx's average Total Assets over the quarter that ended in Mar. 2026 was ₹3,780 Mil. Therefore, 3B BlackBio Dx's annualized ROA % for the quarter that ended in Mar. 2026 was 10.11%.
The historical rank and industry rank for 3B BlackBio Dx's ROA % or its related term are showing as below:
BOM:532067'
s ROA % Range Over the Past 10 Years
Min: 4.55 Med: 16.21 Max: 95.54
Current: 17.32
During the past 13 years, 3B BlackBio Dx's highest ROA % was 95.54%. The lowest was 4.55%. And the median was 16.21%.
BOM:532067's ROA % is ranked better than 95.12% of 1413
companies
in the Biotechnology industry
Industry Median: -32.67
vs BOM:532067: 17.32
3B BlackBio Dx (BOM:532067) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
3B BlackBio Dx ROA % Related Terms
3B BlackBio Dx ROA % Historical Data
* Premium members only.
The historical data trend for 3B BlackBio Dx's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, 3B BlackBio Dx's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3B BlackBio Dx ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3B BlackBio Dx's ROA % distribution charts can be found below:
* The bar in red indicates where 3B BlackBio Dx's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
3B BlackBio Dx (BOM:532067) has a ROA % of 10.11% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on 3B BlackBio Dx and its competitors. This is 38% below median its historical median of 16.21. Over the past decade, 3B BlackBio Dx's ROA % has ranged from 4.55 to 95.54. According to the industry distribution chart, 3B BlackBio Dx ranks #69 out of 1413 companies in the Biotechnology industry, placing it in the top 4.9%.
Is 3B BlackBio Dx's ROA % too high?
3B BlackBio Dx's current ROA % of 10.11% is 38% below median its 10-year median of 16.21. Over the past 10 years, this metric has ranged from a low of 4.55 to a high of 95.54. Based on the distribution chart, 3B BlackBio Dx ranks #69 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 3B BlackBio Dx has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 3B BlackBio Dx's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3B BlackBio Dx ranks #69 out of 1413 companies for ROA %. This places 3B BlackBio Dx in the top 5% of its industry — outperforming the majority of peers. Historically, 3B BlackBio Dx's own ROA % has ranged from 4.55 to 95.54 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on 3B BlackBio Dx and its competitors. 3B BlackBio Dx's current ROA % is 10.11%, which is 38% below median its own 10-year median of 16.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3B BlackBio Dx stock overvalued right now?
Based on GuruFocus' analysis, 3B BlackBio Dx (BOM:532067) is currently considered Possible Value Trap. The stock's GF Value™ is ₹2,108.96, compared to a current price of ₹1,172.50 — trading 44.4% below its estimated fair value. The current ROA % is 10.11%, which is 38% below median its 10-year median of 16.21. 3B BlackBio Dx's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For 3B BlackBio Dx (BOM:532067), the current ROA % is 10.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3B BlackBio Dx (BOM:532067) Overvalued in 2026?
Based on GuruFocus' analysis, 3B BlackBio Dx stock appears to be undervalued.
The current stock price of ₹1,172.50 is trading 44.4% below its estimated GF Value™ of ₹2,108.96.
GuruFocus considers 3B BlackBio Dx to be Possible Value Trap.
Key valuation signals for BOM:532067:
ROA %: 10.11% (38% below median its 10-year median of 16.21)
GF Value™: ₹2,108.96 vs. price of ₹1,172.50 (44.4% below fair value)
No single metric tells the full story. See the BOM:532067 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3B BlackBio Dx Ltd is an Indian company specializing in PCR-based Molecular Diagnostic Kits. The company is involved in designing, developing, manufacturing, and commercializing PCR-based Molecular Diagnostic kits, PCR Enzymes, and PCR Reagents.
68GF Score
Get the complete analysis for BOM:532067
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532067 has been successfully added to your 
